With the FDA decision on Biogen's Aducanumab | IONS Message Board Posts


Ionis Pharmaceuticals, Inc.

  IONS website

IONS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  61596 of 61606  at  6/12/2021 2:01:35 PM  by

riverwalk


 In response to msg 61595 by  Mabel
view thread

Re: With the FDA decision on Biogen's Aducanumab

IMO, This is more likely to have the opposite effect.    
FDA won’t want to be second guessed and crucified over another questionable decision so they will make it tougher for the next candidates.    
Considering the backlash, FDA may even consider applying some more stringent and frequent measuring criteria to BIIB’s drug to deflect some of the criticism.   
And BIIB could defuse this somewhat by cutting the price drastically until they prove it really does slow progression, thus saving care giving costs.   


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0  
   Views: 0 [1]
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
61597 Re: With the FDA decision on Biogen's Aducanumab Mabel 0 6/13/2021 7:51:02 AM


Financial Market Data provided by
.
Loading...